Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SXTP 
60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: SXTP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -66.56% | Avg. Invested days 17 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.61M USD | Price to earnings Ratio 23 | 1Y Target Price 3 |
Price to earnings Ratio 23 | 1Y Target Price 3 | ||
Volume (30-day avg) 1 | Beta 2.79 | 52 Weeks Range 1.22 - 12.45 | Updated Date 10/14/2025 |
52 Weeks Range 1.22 - 12.45 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.07 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -521.27% |
Management Effectiveness
Return on Assets (TTM) -113.11% | Return on Equity (TTM) -294.87% |
Valuation
Trailing PE 23 | Forward PE - | Enterprise Value 13624148 | Price to Sales(TTM) 6.71 |
Enterprise Value 13624148 | Price to Sales(TTM) 6.71 | ||
Enterprise Value to Revenue 21.24 | Enterprise Value to EBITDA 22.23 | Shares Outstanding 4104469 | Shares Floating 3720988 |
Shares Outstanding 4104469 | Shares Floating 3720988 | ||
Percent Insiders 3.13 | Percent Institutions 12.89 |
Upturn AI SWOT
60 Degrees Pharmaceuticals, Inc. Common Stock
Company Overview
History and Background
60 Degrees Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing new medicines for the prevention and treatment of infectious diseases. It was founded to address unmet needs in global health, particularly in the area of travel-related and tropical diseases. Details on exact founding year unavailable in public information.
Core Business Areas
- Drug Development: Focuses on the development of proprietary formulations and new uses for existing molecules to treat infectious diseases.
- Commercialization: Marketing and sales of FDA-approved medications for traveler's diarrhea and malaria prevention.
Leadership and Structure
Information on specific leadership team and organizational structure is not readily available in public sources.
Top Products and Market Share
Key Offerings
- Arakoda (Tafenoquine): A medication for malaria prevention. Competitors include GlaxoSmithKline's Malarone, doxycycline, and mefloquine. Specific market share data is not publicly available.
- Next Generation Traveler's Diarrhea Solution: Targeting traveler's diarrhea. Competitors include Imodium and Pepto-Bismol. Specific market share data is not publicly available.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, driven by innovation and regulation. Companies focus on developing new drugs and therapies to address unmet medical needs.
Positioning
60 Degrees Pharmaceuticals, Inc. is a niche player focused on infectious diseases, differentiating itself through specialized expertise and targeted solutions.
Total Addressable Market (TAM)
The TAM for malaria prevention and treatment is substantial, encompassing travelers, military personnel, and populations in endemic regions. The company's positioning in relation to this TAM is dependent on market penetration and competition.
Upturn SWOT Analysis
Strengths
- Specialized expertise in infectious diseases
- Proprietary formulations
- FDA-approved products
- Focus on unmet medical needs
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on specific product lines
- Limited Market share
- Dependence on regulatory approvals
Opportunities
- Expansion into new markets
- Development of new drugs and therapies
- Strategic partnerships with larger pharmaceutical companies
- Increased awareness of travel-related diseases
Threats
- Competition from larger pharmaceutical companies
- Regulatory changes
- Emergence of drug-resistant pathogens
- Economic downturns
Competitors and Market Share
Key Competitors
- GSK
- PFE
- MRK
Competitive Landscape
60 Degrees Pharmaceuticals, Inc. faces intense competition from larger pharmaceutical companies with greater resources and established market presence. Its advantages lie in its specialized focus and proprietary formulations.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are not publicly available for 60 Degrees Pharmaceuticals, Inc. as a private company.
Future Projections: Future growth projections are not publicly available for 60 Degrees Pharmaceuticals, Inc. as a private company.
Recent Initiatives: Recent initiatives data is not readily available for 60 Degrees Pharmaceuticals, Inc. as a private company.
Summary
60 Degrees Pharmaceuticals is a niche company with a focused approach on infectious diseases and travel medicine. It has the advantage of specialized expertise and FDA-approved products, but faces challenges related to its limited financial resources and competition from larger pharmaceutical companies. To increase its growth, the company should look for opportunities to expand its product portfolio and to form strategic partnerships, whilst managing the ever present regulatory risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- FDA Website
- Industry Reports
Disclaimers:
The information provided is based on publicly available data and analyst estimates. Actual results may vary. Market share information is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About 60 Degrees Pharmaceuticals, Inc. Common Stock
Exchange NASDAQ | Headquaters Washington, DC, United States | ||
IPO Launch date 2023-07-12 | Chairman, CEO & President Dr. Geoffrey Stuart Dow Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://www.60degreespharma.com |
Full time employees 3 | Website https://www.60degreespharma.com | ||
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.